HA-Ubiquitin-propargylamide (human) (rec.) (HA)

Protein. Human ubiquitin (aa1-76) (Accession Nr. P0CG47) with a C-terminal propargylamide group and a N-terminal HA-tag. Source: E. coli. Liquid. In 50mM MES pH 6.0, 100mM sodium chloride. Purity: >97% (LCMS). Ubiquitin is a small (8.5kDa) regulatory protein that has been found in almost all tissues of eukaryotic organisms. The addition of ubiquitin to a substrate protein is called ubiquitination or ubiquitylation. Ubiquitination can affect proteins in many ways: it can signal for their degradation via the proteasome, alter their cellular location, affect their activity and promote or prevent protein interactions. Removal of ubiquitin from a substrate protein occurs via deconjugating enzymes, of which there are nearly 100 known enzymes with various linkage specificities. This product consists of a full-length human, mature ubiquitin polypeptide (amino acids 1-76), expressed in E.coli with a C-terminal warhead (Propargylamide) and a N-terminal HA-tag. HA-Ubiquitin propargylamide is a potent, irreversible and specific inhibitor of deubiquitinating enzymes (DUBs) based on a C-terminal electrophilic propargylamide group. It targets four of the five major DUB families: UCH (Ubiquitin C-terminal hydrolases), USP (Ubiquitin specific proteases), OTU (Ovarian tumor proteases) and MJD (Machado-Josephin domain proteases) while JAMM metalloproteases are not inhibited. HA-Ubiquitin propargylamide can be used for activity profiling experiments and using the HA-Tag conveniently for immunoprecipitations in search for new or novel enzymes reacting with the c-terminal warhead.